Increased incidence of endometrioid tumors caused by aberrations in E-cadherin promoter of mismatch repair-deficient mice

Carcinogenesis

Volumn 32, Issue 7, 2011, Pages 1085-1092

  Kovtun, Irina V ^a   Harris, Kimberly J ^a   Jatoi, Aminah ^a   Jevremovic, Dragan ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CARCINOGENESIS; CHROMOSOME ABERRATION; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; FEMALE; GENITAL SYSTEM; HEMIZYGOSITY; KNOCKOUT MOUSE; LYMPHOMA; MISMATCH REPAIR; MOUSE; NONHUMAN; OVARY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; UTERUS;

EID: 79960073534     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr080     Document Type: Article

References (58)

1. Bellacosa,A. (2001) Functional interactions and signaling properties of mammalian DNA mismatch repair proteins. Cell Death Differ., 8, 1076- 1092.
2. Loeb,L.A. et al. (1974) Errors in DNA replication as a basis of malignant changes. Cancer Res., 34, 2311-2321.
3. Peinado,M.A. et al. (1992) Isolation and characterization of allelic loss and gains in colorectal tumors by arbitrarily primed polymerase chain reaction. Proc. Natl Acad. Sci. USA, 89, 10065-10069.
4. Lynch,H.T. et al. (2003) Hereditary colorectal cancer. N. Engl. J. Med., 348, 919-932.
5. Kane,M.F. et al. (1997) Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res., 57, 808-811.
6. Aarnio,M. et al. (1999) Cancer risk in mutation carriers of DNA-mismatchrepair genes. Int. J. Cancer, 81, 214-218.
7. Chiaravalli,A.M. et al. (2001) Immunohistochemical pattern of hMsh2/hMlh1 in familial and sporadic colorectal, gastric, endometrial and ovarian carcinomas with instability in microsatellite sequences. Vichows Arch., 438, 39-48.
8. Wei,K. et al. (2002) Mouse models for human DNA mismatch-repair gene defects. Trends Mol. Med., 8, 346-353.
9. Jeanes,A. et al. (2008) Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene, 27, 6920-6929.
10. Behrens,J. et al. (1996) Functional interaction of beta-catenin with the transcription factor LEF-1. Nature, 382, 638-642.
11. He,T.C. et al. (1998) Identification of c-MYC as a target of the APC pathway. Science, 281, 1509-1512.
12. Moll,R. et al. (1993) Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am. J. Pathol., 143, 1731-1742.
13. Wu,Z.Y. et al. (2005) Expression of E-cadherin in gastric carcinoma and its correlation with lymph node micrometastasis. World J. Gastroenterol., 11, 3139-3143.
14. Yoshiura,K. et al. (1995) Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc. Natl Acad. Sci. USA, 92, 7416-7419.
15. Yang,J.Y. et al. (2006) MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol. Cell. Biol., 26, 7269-7282.
16. Fujita,Y. et al. (2002) Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat. Cell Biol., 4, 222-231.
17. Gallo,D. et al. (2010) The epithelial-mesenchymal transition and the estrogen-signaling in ovarian cancer. Curr. Drug Targets, 11, 474-481.
18. Vleminckx,K. et al. (1991) Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell, 66, 107-119.
19. Llobet,D. et al. (2009) Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints. J. Clin. Pathol., 62, 777-785.
20. Sundfeldt,K. et al. (1997) E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int. J. Cancer, 74, 275-280.
21. Maines-Bandiera,S.L. et al. (1997) Increased E-cadherin expression in ovarian sutface epithelium: an early step in metaplasia and dysplasia? Int. J. Gynecol. Pathol., 16, 250-255.
22. Tinkle,C.L. et al. (2004) Conditional targeting of E-cadherin in skin: insights into hyperproliferative and degenerative responses. Proc. Natl Acad. Sci. USA, 101, 552-557.
23. Larue,L. et al. (1994) E-cadherin null mutant embryos fail to form a trophectoderm epithelium. Proc. Natl Acad. Sci. USA, 91, 8263-8267.
24. MacCalman,C.D. et al. (1994) Estadiol regulates E-cadherin mRNA levels in the surface epithelium of the mouse ovary. Clin. Exp. Metastasis, 12, 176-282.
25. De Wever,O. et al. (2007) Soluble cadherins as cancer biomarkers. Clin. Exp. Metastasis, 24, 685-697.
26. Kuefer,R. et al. (2003) The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. Clin. Cancer Res., 9, 6447-6452.
27. Cao,Q. et al. (2008) Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene, 27, 7274-7284.
28. Faraldo,M.L. et al. (1997) Analysis of the E-cadherin and P-cadherin promoters in murine keratinocyte cell lines from different stages of mouse skin carcinogenesis. Mol. Carcinog., 20, 33-47.
29. Morse,H.C.III et al. (2002) Hematopathology subcommittee of the mouse models of Human Cancers Consortium. Blood, 100, 246-258.
30. Ricciardone,M.D. et al. (1999) Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. Cancer Res., 59, 290-293.
31. Poley,J.W. et al. Rotterdam Initiative on Gastrointestinal Hereditary Tumors (2007). Biallelic germline mutations of mismatch-repair genes: a possible cause for multiple pediatric malignancies. Cancer, 109, 2349-2356.
32. De Vos,M. et al. (2006) PMS2 mutations in childhood cancer. J. Natl Cancer Inst., 98, 358-361.
33. Kruger,S. et al. (2008) Homozygous PMS2 germline mutations in two families with early-onset haematological malignancy, brain tumours, HNPCC-associated tumours, and signs of neurofibromatosis type 1. Eur. J. Hum. Genet., 16, 62-72.
34. Campbell,M.R. et al. (2005) A lack of DNA mismatch repair on an athymic murine background predisposes to hematologic malignancy. Cancer Res., 65, 2626-2635.
35. Lowsky,R. et al. (2000) MSH2-deficient murine lymphomas harbor insertion/deletion mutations in the transforming growth factor beta receptor type 2 gene and display low not high frequency microsatellite instability. Blood, 95, 1767-1772.
36. Kakinuma,S. et al. (2007) Ikaros is a mutational target for lymphomagenesis in Mlh1-deficient mice. Oncogene, 26, 2945-2949.
37. Auersperg,N. et al. (2008) The origin of ovarian carcinomas: a developmental view. Gynecol. Oncol., 110, 452-454.
38. Orsulic,Y. et al. (2002) Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell, 1, 53-62.
39. Jarboe,E.A. et al. (2008) Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology, 53, 127-138.
40. Hubbard,S.A. et al. (2009) Evidence for cancer stem cells in human endometrial carcinoma. Cancer Res., 69, 8241-8248.
41. Wu,R. et al. (2001) Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res., 61, 8247-8255.
42. Stawerski,P. et al. (2008) Immunoexpression of beta-catenin-E-cadherin complex in primary serous ovarian tumors. Pol. J. Pathol., 59, 27-32.
43. Shaco-Levy,R. et al. (2008) MMP-2, TIMP-1, E-cadherin, and beta-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium. Acta Obstet. Gynecol. Scand., 87, 868-874.
44. Kuraguchi,M. et al. (2001) The distinct spectra of tumor-associated Apc mutations in mismatch repair-deficient Apc1638N mice define the roles of MSH3 and MSH6 in DNA repair and intestinal tumorigenesis. Cancer Res., 61, 7934-7942.
45. Wang,H. et al. (2002) DNA mismatch repair deficiency accelerates endometrial tumorigenesis in Pten heterozygous mice. Am. J. Pathol., 160, 1481-1486.
46. Müler,K.M. et al. (1997) Involvement of E-cadherin in thymus organogenesis and thymocyte maturation. Immunity, 6, 257-264.
47. Armeanu,S. et al. (2000) Involvement of E-cadherin in the development of erythroid cells. Hematology, 5, 307-316.
48. Cor,P.G. et al. (2000) 5' CpG island methylation in acute leukemia. Clin. Cancer Res., 6, 4243-4248.
49. Sharma,S. et al. (2009) Aberrant splicing of the E-cadherin transcript is a novel mechanism of gene silencing in chronic lymphocytic leukemia cells. Blood, 114, 4179-4185.
50. de Yzaguirre,M.M. et al. (2006) Epigenetic silencing of E- and N-cadherins in the stroma of mouse thymic lymphomas. Carcinogenesis, 27, 1081- 1089.
51. Ioannidis,V. et al. (2001) The b-catenin-TCF-1 pathway ensures CD4({thorn}) CD8({thorn}) thymocyte survival. Nat. Immunol., 2, 691-697.
52. Lu,D. et al. (2004) Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA, 101, 3118-3123.
53. Gelebart,P. et al. (2008) Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. Blood, 112, 5171-5179.
54. Groen,R.W. et al. (2008) Illegitimate WNT pathway activation by betacatenin mutation or autocrine stimulation in T-cell malignancies. Cancer Res., 68, 6969-6977.
55. Colella,G. et al. (1999) Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents. Br. J. Cancer, 80, 38-43.
56. Vaisman,A. et al. (1998) The role of hMLH1, hMSH3, hMsh6 defects in cisplatin, oxiplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res., 58, 3579-3585.
57. Howard,E.W. et al. (2008) E-cadherin upregulation as a therapeutic goal in cancer treatment. Mini Rev. Med. Chem., 8, 496-518.
58. Kang,H.G. et al. (2007) E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res., 67, 3094-3105.